Xintela AB (publ) (STO:XINT)
0.2700
-0.0220 (-7.53%)
Feb 5, 2026, 5:12 PM CET
Xintela AB Revenue
Xintela AB had revenue of 855.00K SEK in the quarter ending September 30, 2025, a decrease of -69.70%. This brings the company's revenue in the last twelve months to 2.96M, down -7.68% year-over-year. In the year 2024, Xintela AB had annual revenue of 4.22M with 5,303.85% growth.
Revenue (ttm)
2.96M
Revenue Growth
-7.68%
P/S Ratio
78.64
Revenue / Employee
227.46K
Employees
13
Market Cap
232.54M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 4.22M | 4.14M | 5,303.85% |
| Dec 31, 2023 | 78.00K | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Magle Chemoswed Holding AB | 300.49M |
| Xbrane Biopharma AB | 259.70M |
| Bio-Works Technologies AB | 46.43M |
| Intervacc AB | 21.09M |
| Elicera Therapeutics AB | 13.70M |
| Medivir AB | 3.88M |
| Lipum AB | 398.00K |
| Mendus AB | -1.44M |